Business Wire

NY-SONIC-ENTERPRISES

2.5.2022 14:08:04 CEST | Business Wire | Press release

Share
World-Renowned and Globally Recognized Photographer Anne Geddes Brings Her Artistry and Creativity to NFTs for the First Time With Her Mother’s Day 2022 Collection

Anne Geddes , photographer globally renowned for her iconic imagery capturing the beauty, purity, and joy of new life, brings her artistry and creativity to NFTs for the first time. On May 6, 2022, the Anne Geddes Mother’s Day 2022 NFT Collection will drop at 9 a.m. PT, commemorating the holiday. The Collection contains nine selections made available in a variety of format configurations. Her highly anticipated collection will be sold exclusively through the certified carbon-neutral blockchain marketplace WAX and powered by the Shopify app Waxify . Her renowned artwork will be available for purchase in FIAT (USD) through credit card, PayPal and other traditional payments as well as WAXP, Bitcoin, and Ethereum. This crossover collection seamlessly bridges the gap between the mainstream Anne Geddes photography collectors and avid NFT collectors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220502005269/en/

Buyers can pre-register for the sale at annegeddes.io , with a pre-sale beginning a day prior — May 5, 2022, at 9 a.m. PT.

The configurations of the collection include:

Limited Edition Digital Prints:

All nine images in the Mother's Day collection are minted as digital art prints. Every digital print can be "redeemed" for a corresponding physical 8”x10” print.

Signature Series:

All nine images from the collection make up the “Signature Series.” Every digital print will feature an original authenticated digital signature and a signed physical print. Only 20 of each print will be available for a total of 180 prints. These prints are created exclusively for the Anne Geddes Mother’s Day 2022 NFT Collection.

1-of-1 Collection:

Two images from the collection will be available as limited edition one-of-one digital and physical prints. Each image will feature an authenticated original digital signature and a signed one-of-a-kind physical print.

Each artfully minted NFT will come with an exclusive redemption offering for a physical piece of art, made exclusively for this release. Every NFT will also contain a minted video of Anne personally discussing each of the images. Additionally, all digital and physical prints will be made exclusively for this release and will not be made again in this format.

Anne will also be auctioning off one elusive private shoot in her studio in New York to raise money for mothers and children in Ukraine. An additional commemorative NFT to support Ukrainian children will be available in the gallery to help raise additional funds. All proceeds will be provided to The American Red Cross.

While Anne’s photography has been treasured and respected by many generations, her evocative move into the blockchain with an iconic Anne Geddes Mother's Day NFT Collection is groundbreaking for an artist of this caliber.

Link:

ClickThru

Social Media:

https://www.facebook.com/annegeddes

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release

NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi

Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release

Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in

Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release

Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar

ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release

First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno

BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release

Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye